SXI Stock Analysis: Standex International | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 3.972m USD | 12M Return: 84.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 71.8M
EPS Trend: 15.9%
Qual. Beats: 0
Rev. Trend: 77.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Standex International Corporation (NYSE: SXI) is a diversified industrial manufacturer founded in 1955 and headquartered in Salem, New Hampshire. The company operates through five reporting segments-Electronics, Engineering Technologies, Scientific, Engraving, and Specialty Solutions-serving commercial and industrial markets in the United States and internationally.
Its product portfolio spans a wide range of niche industrial applications, including reed relays, custom electronic sensors, and transformers (marketed under brands such as Standex-Meder, Renco, and Agile Magnetics); mold texturizing and engraving tooling (Piazza Rosa, GS Engineering, Innovent); specialty temperature-controlled equipment for medical, scientific, and pharmaceutical use (American BioTech Supply, Lab Research Products, Cryosafe); net and near-net formed metal components for aerospace, defense, and energy markets (Spincraft, McStarlite); and hydraulic cylinders for trucks and specialty vehicles (Federal, Custom Hoist).
The company is classified within the Industrials sector under the GICS Industrial Machinery & Supplies & Components sub-industry, reflecting its profile as a multi-segment industrial products business serving diversified end markets. Standex uses a multi-brand strategy, with each segment operating under several legacy brand names acquired over time, and serves a broad customer base across aviation, aerospace, defense, energy, medical, and industrial sectors.
- Electronics segment margins pressured by component costs and pricing
- Aerospace and defense backlog growth lifts Engineering Technologies revenue
- Scientific segment normalizes after pandemic-era refrigeration demand surge
| Net Income: 99.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.08 > 1.0 |
| NWC/Revenue: 36.63% < 20% (prev 45.95%; Δ -9.32% < -1%) |
| CFO/TA 0.05 > 3% & CFO 79.6m > Net Income 99.0m |
| Net Debt (467.2m) to EBITDA (229.5m): 2.04 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.1m) vs 12m ago 0.02% < -2% |
| Gross Margin: 39.81% > 18% (prev 39.21%; Δ 0.60% > 0.5%) |
| Asset Turnover: 57.47% > 50% (prev 48.13%; Δ 9.34% > 0%) |
| Interest Coverage Ratio: 5.73 > 6 (EBIT TTM 190.1m / Interest Expense TTM 33.2m) |
| A: 0.21 (Total Current Assets 482.7m - Total Current Liabilities 158.4m) / Total Assets 1.53b |
| B: 0.79 (Retained Earnings 1.20b / Total Assets 1.53b) |
| C: 0.12 (EBIT TTM 190.1m / Avg Total Assets 1.54b) |
| D: 1.04 (Book Value of Equity 754.2m / Total Liabilities 728.4m) |
| Altman-Z'' = 5.87 = AAA |
| DSRI: 0.83 (Receivables 222.9m/228.3m, Revenue 885.4m/748.3m) |
| GMI: 0.98 (GM 39.21% / 39.81%) |
| AQI: 0.98 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.18 (Revenue 885.4m / 748.3m) |
| TATA: 0.01 (NI 99.0m - CFO 79.6m) / TA 1.53b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 301.25 with a total of 135,153 shares traded. Over the past week, the price has changed by -15.77%, over one month by +2.50%, over three months by +10.56% and over the past year by +84.48%.
Current recommended Stop Loss: 280.90 (which is 6.8% or 1.3 ATR below the current price).
Standex International has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy SXI.
- StrongBuy: 2
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 290.8 | -3.5% |
P/E Trailing = 39.8869
P/E Forward = 37.3134
P/S = 4.4863
P/B = 5.5976
P/EG = 0.9516
Revenue TTM = 885.4m USD
EBIT TTM = 190.1m USD
EBITDA TTM = 229.5m USD
Long Term Debt = 472.8m USD (from longTermDebt, last quarter)
Short Term Debt = 12.5m USD (from shortTermDebt, last quarter)
Debt = 571.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 49.1m
Net Debt = 467.2m USD (calculated: Debt 571.0m - CCE 103.7m)
Enterprise Value = 4.44b USD (3.97b + Debt 571.0m - CCE 103.7m)
Interest Coverage Ratio = 5.73 (Ebit TTM 190.1m / Interest Expense TTM 33.2m)
EV/FCF = 81.80x (Enterprise Value 4.44b / FCF TTM 54.3m)
FCF Yield = 1.22% (FCF TTM 54.3m / Enterprise Value 4.44b)
FCF Margin = 6.13% (FCF TTM 54.3m / Revenue TTM 885.4m)
Net Margin = 11.18% (Net Income TTM 99.0m / Revenue TTM 885.4m)
Gross Margin = 39.81% ((Revenue TTM 885.4m - Cost of Revenue TTM 533.0m) / Revenue TTM)
Gross Margin QoQ = 38.98% (prev 39.67%)
Tobins Q-Ratio = 2.91 (Enterprise Value 4.44b / Total Assets 1.53b)
Interest Expense / Debt = 5.81% (Interest Expense 33.2m / Debt 571.0m)
Taxrate = 23.16% (36.3m / 156.9m)
NOPAT = 146.0m (EBIT 190.1m * (1 - 23.16%))
Current Ratio = 3.05 (Total Current Assets 482.7m / Total Current Liabilities 158.4m)
Debt / Equity = 0.76 (Debt 571.0m / totalStockholderEquity, last quarter 754.2m)
Debt / EBITDA = 2.04 (Net Debt 467.2m / EBITDA 229.5m)
Debt / FCF = 8.61 (Net Debt 467.2m / FCF TTM 54.3m)
Total Stockholder Equity = 718.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.42% (Net Income 99.0m / Total Assets 1.53b)
RoE = 13.78% (Net Income TTM 99.0m / Total Stockholder Equity 718.4m)
RoCE = 15.96% (EBIT 190.1m / Capital Employed (Equity 718.4m + L.T.Debt 472.8m))
RoIC = 10.93% (NOPAT 146.0m / Invested Capital 1.34b)
WACC = 9.63% (E(3.97b)/V(4.54b) * Re(10.37%) + D(571.0m)/V(4.54b) * Rd(5.81%) * (1-Tc(0.23)))
Discount Rate = 10.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 0.76%
[DCF] Terminal Value 73.95% ; FCFF base≈47.9m ; Y1≈54.9m ; Y5≈80.9m
[DCF] Fair Price = 43.41 (EV 993.2m - Net Debt 467.2m = Equity 525.9m / Shares 12.1m; r=9.63% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 15.90 | EPS CAGR: 2.56% | SUE: 0.0 | # QB: 0
Revenue Correlation: 77.28 | Revenue CAGR: 6.90% | SUE: -0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.17 | Chg30d=+0.00% | Revisions=-25% | Analysts=4
EPS current Year (2026-06-30): EPS=8.66 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+8.6% | GrowthRev=+12.6%
EPS next Year (2027-06-30): EPS=9.96 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+15.0% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -30% (up=2, down=5)